[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55364A - Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers - Google Patents

Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers

Info

Publication number
MA55364A
MA55364A MA055364A MA55364A MA55364A MA 55364 A MA55364 A MA 55364A MA 055364 A MA055364 A MA 055364A MA 55364 A MA55364 A MA 55364A MA 55364 A MA55364 A MA 55364A
Authority
MA
Morocco
Prior art keywords
methods
bioconjugates
coli
producing
polysaccharidic
Prior art date
Application number
MA055364A
Other languages
English (en)
Inventor
Darren Robert Abbanat
Martin Edward Braun
Pieter Jan Burghout
Sandmeier Maria Paula Carranza
Kellen Cristhina Fae
Fonck Veronica Gambillara
Jeroen Geurtsen
Yon Patricia Ibarra
Stefan Jochen Kemmler
Michael Thomas Kowarik
Manuela Mally
Jan Theunis Poolman
Eveline Marleen Weerdenburg
Original Assignee
Glaxosmithkline Biologicals Sa
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Janssen Pharmaceuticals Inc filed Critical Glaxosmithkline Biologicals Sa
Publication of MA55364A publication Critical patent/MA55364A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MA055364A 2019-03-18 2020-03-18 Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers MA55364A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962819746P 2019-03-18 2019-03-18

Publications (1)

Publication Number Publication Date
MA55364A true MA55364A (fr) 2022-01-26

Family

ID=70285927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055364A MA55364A (fr) 2019-03-18 2020-03-18 Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers

Country Status (23)

Country Link
US (3) US11446370B2 (fr)
EP (1) EP3941516A1 (fr)
JP (1) JP7370391B2 (fr)
KR (1) KR102532707B1 (fr)
CN (1) CN113924112A (fr)
AR (1) AR118388A1 (fr)
AU (1) AU2020240072A1 (fr)
BR (1) BR112021018236A2 (fr)
CA (1) CA3134216A1 (fr)
CL (1) CL2021002426A1 (fr)
CO (1) CO2021013823A2 (fr)
CR (1) CR20210522A (fr)
EA (1) EA202192390A1 (fr)
IL (1) IL286394A (fr)
JO (1) JOP20210256A1 (fr)
MA (1) MA55364A (fr)
MX (1) MX2021011445A (fr)
PE (1) PE20212265A1 (fr)
SA (1) SA521430310B1 (fr)
SG (1) SG11202110301TA (fr)
TW (1) TWI751513B (fr)
UY (1) UY38616A (fr)
WO (1) WO2020191082A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
SI3110441T1 (sl) 2014-02-24 2024-07-31 Glaxosmithkline Biologicals S.A. Novi polisaharidi in njihova uporaba
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
MA55364A (fr) 2019-03-18 2022-01-26 Glaxosmithkline Biologicals Sa Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
TWI771663B (zh) 2019-03-18 2022-07-21 美商詹森藥物公司 E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法
BR112023004819A2 (pt) * 2020-09-17 2023-04-18 Janssen Pharmaceuticals Inc Composições de vacinas multivalentes e seus usos
JP7495578B2 (ja) 2020-11-30 2024-06-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド キャピラリーベースのイムノアッセイシステムを使用する複合糖質の分析方法
AU2022251305A1 (en) 2021-04-01 2023-09-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
WO2022214620A1 (fr) 2021-04-08 2022-10-13 Janssen Pharmaceuticals, Inc. Procédé de production de bioconjugués
CN116003531B (zh) * 2022-12-28 2023-09-05 山东省农业科学院畜牧兽医研究所 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
TR199902437T2 (xx) 1997-04-01 2000-01-21 Corixa Corporation Monofosforil lipid A'ya ait sulu im�nolojik adjuvant terkipleri.
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2773698C (fr) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Systemes d'adjuvants comprenant un immunostimulant absorbe sur une part cule de sel metallique et vaccins derives
WO2001078777A2 (fr) 2000-04-13 2001-10-25 Mossman, Sally COMPOSITIONS IMMUNOSTIMULANTES COMPRENANT UN PHOSPHATE D'AMINOALKYL GLUCOSAMINIDE ET DU QS-21
CA2406229C (fr) 2000-04-18 2010-09-07 Endobiologics, Incorporated Vaccin conjugue anti-sepsie
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
WO2003074679A2 (fr) 2002-03-01 2003-09-12 Xencor Optimisation d'anticorps
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
CA2561577A1 (fr) 2004-03-30 2005-10-13 Nsgene A/S Utilisation therapeutique d'un facteur de croissance, nsg33
KR101524636B1 (ko) 2005-05-11 2015-06-03 에테하 취리히 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646891A1 (fr) 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
CA2964398C (fr) 2007-09-14 2023-03-07 Adimab, Llc Bibliotheques d'anticorps synthetiques rationnelles et leurs utilisations
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
JP5782258B2 (ja) 2008-02-20 2015-09-24 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
EP3461840A1 (fr) 2009-04-27 2019-04-03 Immuron Limited Préparation d'immunoglobuline enrichie en anti-lps destinée au traitement et/ou à la prophylaxie de la stéatohépatite non alcoolique
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
US8846342B2 (en) 2009-11-19 2014-09-30 Glycovaxyn Ag Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
JP2014502595A (ja) 2010-12-10 2014-02-03 メルク・シャープ・アンド・ドーム・コーポレーション 免疫原性組成物の撹拌誘導凝集を緩和する新規な製剤
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
WO2014037585A1 (fr) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugués comprenant des antigènes modifiés et leurs utilisations
EP3527663B1 (fr) 2012-10-12 2021-12-01 GlaxoSmithKline Biologicals SA Methode pour modifier des cellules
CA2896157A1 (fr) 2012-12-27 2014-07-03 Glycovaxyn Ag Procedes et compositions se rapportant a crm197
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
ME03586B (fr) 2013-05-18 2020-07-20 Univ California Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
SG11201602546RA (en) 2013-10-11 2016-04-28 Glycovaxyn Ag Methods of host cell modification
AU2014359277B2 (en) 2013-12-04 2017-10-26 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
US12103962B2 (en) 2014-02-06 2024-10-01 X4 Pharmaceuticals (Austria) GmbH E. coli specific antibodies
SI3110441T1 (sl) * 2014-02-24 2024-07-31 Glaxosmithkline Biologicals S.A. Novi polisaharidi in njihova uporaba
BR112016023688B1 (pt) 2014-04-17 2024-01-09 Glaxosmithkline Biologicals Sa Bioconjugado e uso de um bioconjugado
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
EP3240895B1 (fr) * 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions et methodes pour la glycosylation de proteine
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
TWI771663B (zh) 2019-03-18 2022-07-21 美商詹森藥物公司 E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法
MA55364A (fr) 2019-03-18 2022-01-26 Glaxosmithkline Biologicals Sa Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
BR112023004819A2 (pt) 2020-09-17 2023-04-18 Janssen Pharmaceuticals Inc Composições de vacinas multivalentes e seus usos

Also Published As

Publication number Publication date
KR20210141586A (ko) 2021-11-23
KR102532707B1 (ko) 2023-05-12
SA521430310B1 (ar) 2023-12-13
AR118388A1 (es) 2021-09-29
TW202102255A (zh) 2021-01-16
MX2021011445A (es) 2021-10-13
EP3941516A1 (fr) 2022-01-26
JOP20210256A1 (ar) 2023-01-30
US20200316184A1 (en) 2020-10-08
CO2021013823A2 (es) 2022-03-29
CL2021002426A1 (es) 2022-04-29
CR20210522A (es) 2021-12-17
US11931405B2 (en) 2024-03-19
WO2020191082A9 (fr) 2020-11-05
JP7370391B2 (ja) 2023-10-27
IL286394A (en) 2021-10-31
BR112021018236A2 (pt) 2021-11-23
AU2020240072A1 (en) 2021-10-28
US20240316172A1 (en) 2024-09-26
EA202192390A1 (ru) 2021-12-03
PE20212265A1 (es) 2021-11-30
US20230118878A1 (en) 2023-04-20
TWI751513B (zh) 2022-01-01
UY38616A (es) 2020-09-30
JP2022533883A (ja) 2022-07-27
SG11202110301TA (en) 2021-10-28
WO2020191082A1 (fr) 2020-09-24
CA3134216A1 (fr) 2020-09-24
CN113924112A (zh) 2022-01-11
US11446370B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
MA55364A (fr) Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
CA200051S (fr) Boucle d'oreille
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
CA189234S (fr) Boucle d'oreille
EP3733809A4 (fr) Composition d'agent hydrofuge, et procédé de production de produit fibreux hydrofuge
WO2018109174A3 (fr) Anticorps anti-il-11
WO2018109170A3 (fr) Anticorps il-11ra
MA55365A (fr) Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation
PH12020551716A1 (en) Anti-ror antibody constructs
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
CA189957S (fr) Boucle d'oreille
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
EP3865612A4 (fr) Tissu nouveau présentant une structure en réseau formée par des touffes de fibres de collagène, et produit en cuir nouveau
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CA189215S (fr) Boucle d'oreille
CA185201S (fr) Boucle d'oreilles
EP3452084A4 (fr) Anticorps anti-kv 1.3 et procédés pour les produire et les utiliser
DK3762341T3 (da) Glassammensætninger, glassammensætninger til fremstilling af glasfibre, og glasfibre fremstillet deraf
BR112021020367A2 (pt) Formas sólidas de (e)-3-[2-(2-tienil)vinil] -1h-pirazol
CY1125463T1 (el) Διαμορφωτες διαυλου καλιου
WO2020123330A3 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MX2021006682A (es) Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson.
EP3498708A4 (fr) Dérivés de 3- (4,5-substitué pyrimidinamine) phényle deutérés et leurs applications